Last reviewed · How we verify
NCT02947373
Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors
Phase 1 trial testing Hyperpolarized Pyruvate in Pediatric Brain Tumors in 10 participants. Completed in 31 July 2020.
30 April 2020
Quick facts
| Lead sponsor | University of California, San Francisco |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 10 |
| Start date | 25 January 2017 |
| Primary completion | 30 April 2020 |
| Estimated completion | 31 July 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hyperpolarized Pyruvate — full drug profile →
Conditions studied
- Pediatric Brain Tumors — all drugs for Pediatric Brain Tumors →
Sponsor
University of California, San Francisco
Who can join
Adults 3 to 18, any sex, with Pediatric Brain Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The pilot study will look at the safety and toxicity of acquiring hyperpolarized carbon-13 imaging in children with brain tumors.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Comprehensive Literature Review of Hyperpolarized Carbon-13 MRI: The Road to Clinical Application.
Vaeggemose M, F Schulte R, Laustsen C. · · 2021 · cited 35× · PMID 33916803 · DOI 10.3390/metabo11040219 -
Metabolic response to radiation therapy in cancer.
Read GH, Bailleul J, Vlashi E, Kesarwala AH. · · 2022 · cited 25× · PMID 34961986 · DOI 10.1002/mc.23379 -
Pilot Study of Hyperpolarized <sup>13</sup>C Metabolic Imaging in Pediatric Patients with Diffuse Intrinsic Pontine Glioma and Other CNS Cancers.
Autry AW, Park I, Kline C, Chen HY, et al · · 2021 · cited 19× · PMID 33272950 · DOI 10.3174/ajnr.a6937
Verify or expand the search:
- PubMed search for NCT02947373
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of California, San Francisco trials
Trials by the same sponsor.
- NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
- NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
- NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
- NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
- NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02947373 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
- Last refreshed: 24 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02947373.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing